SoloPak Obtains Rights to Ganite

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 2
Volume 4
Issue 2

ELK GROVE VILLAGE, Ill--SoloPak Pharmaceuticals, Inc. has signed an agreement with Sloan-Kettering Institute for Cancer Research to acquire the exclusive worldwide rights to gallium nitrate (Ganite), which was FDA approved in 1991 for the treatment of acute hypercalcemia in cancer patients and had been manufactured by Fujisawa USA (Deerfield, Ill).

ELK GROVE VILLAGE, Ill--SoloPak Pharmaceuticals, Inc. has signedan agreement with Sloan-Kettering Institute for Cancer Researchto acquire the exclusive worldwide rights to gallium nitrate (Ganite),which was FDA approved in 1991 for the treatment of acute hypercalcemiain cancer patients and had been manufactured by Fujisawa USA (Deerfield,Ill).

The agreement involves a grant of SoloPak equity to the Instituteand a commitment of funds from SoloPak to complete clinical trials.

Over the next 2 to 3 years, SoloPak plans to seek approval ofgallium nitrate for the treatment of chronic hypercalcemia andbone metastases in cancer patients, and to launch clinical trialsof the agent in Paget's disease and osteoporosis.

Articles in this issue
FTC Advised to List Tar and Nicotine Levels Directly on Cigarette Packages
Multidisciplinary Approach Urged For Pain Relief
FDA Approves New Indication for Neupogen: Chronic Neutropenia
Department of Labor Wants to Study Possible Occupation-Cancer Links
Undertreatment of Cancer-Related Pain May Be Tied to Physicians' Fear of Addiction to Drugs
Navelbine Is Now Available for Use in Inoperable Advanced Stage NSCLC
ASH Panel: How Many Hemotologists/Oncologists Are Enough?
Mammography Van Brings Breast Cancer Screening to the Workplace
FDA to Build $600 Million Campus
Finasteride Studied as Prostate Ca Preventive
Panel Fails to Recommend Taxotere as Treatment for Breast and Lung Cancer
Thrombopoietin Raises Platelet Counts in Animals
Major Cancer Centers Form Network to Negotiate With Insurers
ACS Panel on Prostate Cancer: Painful Skeletal Mets Require Special Management
Liposomal Tretinoin in Phase II/III Trials in Kaposi's Sarcoma Patients
Recent Videos
Lisa J. States, MD, discussed further steps for improving early detection and screening methods in patients with Li–Fraumeni syndrome.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
9 Experts are featured in this series.
9 Experts are featured in this series.
Additional genetic testing measures and targeted therapies may improve outcomes for patients with diverse molecular subgroups of gastric cancers.
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
Related Content
IDE397 Shows Preliminary Efficacy in MTAP+ NSCLC and Urothelial Cancer

IDE397 Shows Preliminary Efficacy in MTAP+ NSCLC and Urothelial Cancer

Russ Conroy
October 28th 2024
Article

Phase 1 expansion data may support potential combination development for IDE397 in NSCLC and urothelial cancer harboring MTAP deletions.

Ginger J. Gardner, MD, FACOG, highlights disease prevention innovations and other ongoing efforts to empower education in the gynecologic cancer field.

Empowering Awareness to Address Rising Gynecological Cancer Incidence

Ginger J. Gardner, MD, FACOG
October 28th 2024
Podcast

Ginger J. Gardner, MD, FACOG, highlights disease prevention innovations and other ongoing efforts to empower education in the gynecologic cancer field.

Mitigating Adverse Effects Following GPRC5DTargeted Therapy in Multiple Myeloma

Mitigating Adverse Effects Following GPRC5DTargeted Therapy in Multiple Myeloma

ONCOLOGY Staff
October 27th 2024
Article

A panel of experts in multiple myeloma discussed strategies for monitoring and mitigating adverse effects associated with GPRC5D-targeting bispecific agents.

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Leveraging Ex Vivo Gene Therapy Advancements in Hemoglobinopathies and Metabolic Diseases

Alexis K. Kuhn, PharmD, BCOP ;Katie Bruce, PharmD, BCPPS;Susie Long, PharmD
October 21st 2024
Podcast

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Evaluating Immunotherapy Options Based on Mutations for NSCLC

Evaluating Immunotherapy Options Based on Mutations for NSCLC

ONCOLOGY Staff
October 26th 2024
Article

Experts discussed the efficacy and durability of immunotherapy responses in patients with NSCLC.

Promising phase 1 data appear to support further evaluation of ZL-1310 as a treatment for patients with extensive-stage small cell lung cancer.

DLL3-Targeted ADC Produces Responses in Previously Treated ES-SCLC

Russ Conroy
October 25th 2024
Article

Promising phase 1 data appear to support further evaluation of ZL-1310 as a treatment for patients with extensive-stage small cell lung cancer.